Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker PCRX
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 12, 2026 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 5, 2026 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 8, 2026 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 8, 2026 | PCRX Pacira BioSciences, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 4, 2026 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 30, 2026 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 30, 2026 | PCRX Pacira BioSciences, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jun 11, 2026 | PCRX Pacira BioSciences, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 11, 2026 | PCRX Pacira BioSciences, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 11, 2026 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 30, 2026 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 26, 2026 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 28, 2026 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 28, 2026 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jan 8, 2026 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 6, 2025 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 5, 2025 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 10, 2025 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 10, 2025 | PCRX Pacira BioSciences, Inc. | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Jul 7, 2025 | PCRX Pacira BioSciences, Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jul 7, 2025 | PCRX Pacira BioSciences, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 7, 2025 | PCRX Pacira BioSciences, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jun 13, 2025 | PCRX Pacira BioSciences, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 13, 2025 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 8, 2025 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 22, 2025 | PCRX Pacira BioSciences, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Apr 7, 2025 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 7, 2025 | PCRX Pacira BioSciences, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 14, 2025 | PCRX Pacira BioSciences, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Feb 27, 2025 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 30, 2025 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 30, 2025 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jan 21, 2025 | PCRX Pacira BioSciences, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 21, 2025 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jan 10, 2025 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 6, 2024 | PCRX Pacira BioSciences, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 6, 2024 | PCRX Pacira BioSciences, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
37 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:41 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances